Letter to the Editor: In Response to Hematology...Literally and Seriously
Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.
A New Phase II Agent Holds Promise for First FDA Approved Therapy for Treatment of Acute Vaso-Occlusive Pain Events in SCD
Dr. DeBaun evaluates a new agent for the prevention of vaso-occlusive pain episodes in sickle cell disease that holds promise for first FDA approval since hydroxyurea.
Dr. Roberts considers challenges remain regarding CLL therapy in patients at higher risk for relapse and those facing progression on a kinase inhibitor.
Dr. Stieglitz and Dr. Koegel discuss genetic markers and risk stratification algorithms to guide individualized treatment of juvenile myelomonocytic leukemia.
Drs. John Byrd, Elizabeth Raetz and Eytan Stein discuss the trial's design, rationale, and results, as well as its significance in developing a precision medicine approach to treat AML.
March/April 2017 Volume 14, Issue 2
View all Features articles
View all Diffusion articles
Dr. Kenneth Anderson offers insight into the Society's official policy statements.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
The House of Representatives released legislation, titled
the “American Health Care Act,” to repeal the Affordable Care Act. As
written, ASH has serious concerns that this legislation will reduce overall
access to coverage and treatment and would greatly impact patients with
hematologic diseases and disorders.
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology